{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,9]],"date-time":"2026-01-09T14:23:08Z","timestamp":1767968588297,"version":"3.49.0"},"reference-count":20,"publisher":"Public Library of Science (PLoS)","issue":"4","license":[{"start":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T00:00:00Z","timestamp":1555027200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Associazione Italiana Contro le Leucemie Sezione Bruno Rotoli Napoli","award":["10.000 euro"],"award-info":[{"award-number":["10.000 euro"]}]}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"DOI":"10.1371\/journal.pone.0215295","type":"journal-article","created":{"date-parts":[[2019,4,12]],"date-time":"2019-04-12T17:37:10Z","timestamp":1555090630000},"page":"e0215295","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":10,"title":["Single center experience on efficacy and safety of Aprepitant for preventing chemotherapy-induced nausea and vomiting (CINV) in pediatric Hodgkin Lymphoma"],"prefix":"10.1371","volume":"14","author":[{"given":"Giovanna","family":"Giagnuolo","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Salvatore","family":"Buffardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Francesca","family":"Rossi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fara","family":"Petruzziello","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chiara","family":"Tortora","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabella","family":"Buffardi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nicoletta","family":"Marra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuliana","family":"Beneduce","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Giuseppe","family":"Menna","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3350-5286","authenticated-orcid":true,"given":"Rosanna","family":"Parasole","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2019,4,12]]},"reference":[{"issue":"6","key":"ref1","doi-asserted-by":"crossref","first-page":"414","DOI":"10.3747\/co.19.1074","article-title":"Prospective validation of risk prediction indexes for acute and delayed chemotherapy-induced nausea and vomiting","volume":"19","author":"N Bougamin","year":"2012","journal-title":"Cur Oncol"},{"issue":"Suppl 1","key":"ref2","first-page":"S37","article-title":"Antiemetics in children receiving chemotherapy. MASCC\/ESMO guideline update 2009","volume":"2011","author":"K Jordan","journal-title":"Support Care Cancer"},{"issue":"31","key":"ref3","doi-asserted-by":"crossref","first-page":"4189","DOI":"10.1200\/JCO.2010.34.4614","article-title":"Antiemetics: American Society of Clinical Oncology Practice Guideline Update","volume":"29","author":"E Basch","year":"2011","journal-title":"J Clin Oncol"},{"key":"ref4","article-title":"Product Monograph","year":"2017"},{"key":"ref5","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/pbc.21811","article-title":"Aprepitant in adolescent patients for prevention of chemotherapy-induced nausea and vomiting: a randomized, double-blind, placebo-controlled study of efficacy and tolerability","volume":"52","author":"L Gore","year":"2009","journal-title":"Pediatr Blood Cancer"},{"key":"ref6","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1007\/s11096-013-9842-4","article-title":"Emesis control by aprepitant in children and adolescents with chemotherapy","volume":"35","author":"TGM Bauters","year":"2013","journal-title":"Int J Clin Pharm"},{"key":"ref7","doi-asserted-by":"crossref","first-page":"1073","DOI":"10.1002\/pbc.24508","article-title":"Guideline for the prevention of acute nausea and vomiting due to antineoplastic medication in pediatric cancer patients","volume":"60","author":"LL Dupuis","year":"2013","journal-title":"Pediatr Blood Cancer"},{"issue":"1","key":"ref8","doi-asserted-by":"crossref","first-page":"323","DOI":"10.1007\/s00520-016-3384-y","article-title":"2016 updated MASCC\/ESMO consensus recommendations: prevention of acute chemotherapy-induced nausea and vomiting in children","volume":"25","author":"LL Dupuis","year":"2017","journal-title":"Support Care Cancer"},{"issue":"4","key":"ref9","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S1470-2045(15)70061-6","article-title":"Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in children: a randomized, double blind, phase 3 trial","volume":"16","author":"HJ Kang","year":"2015","journal-title":"Lancet Oncol"},{"key":"ref10","doi-asserted-by":"crossref","first-page":"3229","DOI":"10.1007\/s00520-015-2714-9","article-title":"Aprepitant as an add-on therapy in children receiving highly emetogenic chemotherapy: a randomized, double blind, placebo controlled trial","volume":"23","author":"S Bakhshi","year":"2015","journal-title":"Support. Care Cancer"},{"key":"ref11","article-title":"Acute chemotherapy-induced nausea and vomiting in children with cancer: still waiting for a common consensus on treatment","author":"A Ruggiero","year":"2018","journal-title":"J Int Med Res"},{"key":"ref12","article-title":"Aprepitant for the prevention of chemotherapy-induced nausea and vomiting in paediatric subjects: An analysis by age group","author":"HJ Kang","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"ref13","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1002\/pbc.23114","article-title":"Guidelines for the classification of the acute emetogenic potential of antineoplastic medication in pediatric cancer patient","volume":"57","author":"LL Dupuis","year":"2011","journal-title":"Pediatr Blood Cancer"},{"issue":"10","key":"ref14","doi-asserted-by":"crossref","DOI":"10.1002\/pbc.26542","article-title":"Guidelines for the prevention of acute chemotherapy-induced nausea and vomiting in pediatric cancer patients: a focused update","volume":"64","author":"P Patel","year":"2017","journal-title":"Pediatr Blood Cancer"},{"issue":"6","key":"ref15","doi-asserted-by":"crossref","first-page":"e1542","DOI":"10.1542\/peds.2010-1410","article-title":"Development and Validation of a Pictorial Nausea Rating Scale for Children","volume":"127","author":"AL Baxter","year":"2011","journal-title":"Pediatrics"},{"issue":"5","key":"ref16","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3109\/10428194.2015.1083561","article-title":"Prognostic relevance of DHAP dose-density in relapsed Hodgkin lymphoma: an analysis of the German Hodgkin-Study Group","volume":"57","author":"S Sasse","year":"2016","journal-title":"Leuk Lymphoma"},{"key":"ref17","first-page":"28","article-title":"National Cancer Institutes of Health, Division of Cancer Treatment and Diagnosis","year":"2009"},{"issue":"1","key":"ref18","doi-asserted-by":"crossref","first-page":"e0169393","DOI":"10.1371\/journal.pone.0169393","article-title":"Development of the Liverpool Adverse Drug Reaction Avoidability Assessment Tool","volume":"12","author":"LE Bracken","year":"2017","journal-title":"PLoS One"},{"issue":"4","key":"ref19","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1213\/ANE.0b013e3181ff47e2","article-title":"A comparison of the combination of aprepitant and dexamethasone versus the combination of ondansetron and dexamethasone for the prevention of postoperative nausea and vomiting in patients undergoing craniotomy","volume":"112","author":"AS Habib","year":"2011","journal-title":"Anesth Analg"},{"issue":"3","key":"ref20","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1177\/1078155218755547","article-title":"Adverse events associated with aprepitant pediatric bone cancer patients","volume":"25","author":"LM Okumara","year":"2019","journal-title":"J Oncol Pharm Pract"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/dx.plos.org\/10.1371\/journal.pone.0215295","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,9,15]],"date-time":"2022-09-15T22:04:26Z","timestamp":1663279466000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0215295"}},"subtitle":[],"editor":[{"given":"Robert S.","family":"Benjamin","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2019,4,12]]},"references-count":20,"journal-issue":{"issue":"4","published-online":{"date-parts":[[2019,4,12]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0215295","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,4,12]]}}}